Precision biosciences inc stock.

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …Tesla’s stock is predicted to increase in value in 2015, according to Forbes. In January 2015, Forbes noted that Tesla Motors, Inc.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...WebRevenue. $115.5 million [1] Number of employees. 192 [2] (2022) Website. precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using ...Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00.

Nov 21, 2023 · On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock jump 2.61% to $0.45. On the same session, the stock had its day’s lowest price of $0.44, but rose to a high of $0.4695. Over the last five days, the stock has gained 30.61%. Precision Biosciences Inc shares have fallen nearly -62.35% since the year began. Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...

As of November 28, 2023, 4:00 PM, CST, Avidity Biosciences Inc’s stock price was $7.08. Avidity Biosciences Inc is up 14.94% from its previous closing price of $6.16. During the last market session, Avidity Biosciences Inc’s stock traded between $5.97 and $6.25. Currently, there are 74.10 million shares of Avidity Biosciences Inc stock ...

On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum ...Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...Investor Contact. Tim Kelly. (857) 702-9452. Email: [email protected]. The Investor Relations website contains information about Praxis Precision Medicines, Inc.'s business for stockholders, potential investors, and financial analysts.

BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT. HC Wainwright Lowers Price Target on Precision BioSciences to $17 from $20, Keeps Buy Rating. Nov. 10. MT.

Precision BioSciences Inc (DTIL) stock is higher by 1.82% while the S&P 500 has fallen -0.2% as of 3:24 PM on Tuesday, Feb 28. DTIL is higher by $0.02 from the previous closing price of $1.10 on volume of 308,757 shares. Over the past year the S&P 500 has fallen -9.14% while DTIL has fallen -73.65%.Web

DTIL Precision Biosciences Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select …Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00.(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that decreased from last year and missed the Street estimates.... (RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that de...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3900 -0.0099 (-2.48%) At close: 04:00PM EST. 0.3896 -0.00 (-0.10%) After hours: 07 ...

DTIL Precision Biosciences Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)Nov 6, 2023 · Precision BioSciences Inc, a biotechnology company, has been attracting attention from investors due to its potential for growth. On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value. Stock Exchange: NASDAQ. Precision BioSciences: Culture. 233 articles about Precision BioSciences, Inc. ... Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an …DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.“Our progress in the first …WebUnder the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging ...Precision Biosciences does dabble in both medical applications and food via its subsidiary, Elo Life Systems CRISPR companies are relatively richly valued (CRSP at 14.5B market cap, EDIT at 5B) whereas DTIL is only …

DURHAM, N.C., April 20, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...

Common stock . This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share. Prior to this offering, there has been no public market for our common stock.DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ...Aug 15, 2023 · DURHAM, N.C., August 15, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today ... Precision BioSciences Inc. is based in Durham, North Carolina. Stock Name, Country, Market Cap, PE Ratio. Amgen (AMGN), United States, $144.423B, 14.97. Bristol ...Precision BioSciences Annual Revenue Estimates (Precision BioSciences) The company’s market cap is about $152M, so that would be a roughly 0.3x forward price-to-sales. Considering the industry ...November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ...

Nov 21, 2023 · On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock jump 2.61% to $0.45. On the same session, the stock had its day’s lowest price of $0.44, but rose to a high of $0.4695. Over the last five days, the stock has gained 30.61%. Precision Biosciences Inc shares have fallen nearly -62.35% since the year began.

With a price-to-sales (or "P/S") ratio of 3.8x Precision BioSciences, Inc. (NASDAQ:DTIL) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in ...Web

Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...See Precision BioSciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. We note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.15 million. Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50.November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Get the latest stock price for Precision BioSciences Inc. (DTIL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings.Is "Precision Biosciences Inc" a Good Investment? Current price today: △0.424 USD (+1.631%). 7 Days Forecast. Get It Now!Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of …Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00. Revenue. $115.5 million [1] Number of employees. 192 [2] (2022) Website. precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using ...

See Precision BioSciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. Nov 9, 2023 · On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...Instagram:https://instagram. corvette 70th anniversary pricehigh paying dividend reitsnon qualifying mortgage lendersvision energy corporation news SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company … how to sell stock on etradegood brokers for forex Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at ... top 10 investment firms Get Our Latest Stock Report on Precision BioSciences. Precision BioSciences Stock Performance. NASDAQ:DTIL traded up $0.01 during trading on Monday, reaching $0.38. The company’s stock had a ...Yu: Precision BioSciences: Current Employment, Current equity holder in publicly-traded company. Heery: Precision BioSciences: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Arcellx: Current Employment, Current holder of stock options in a privately-held company.